As NV driven by VEGF-A is responsible for the blindness that occurs with AMD and DR [3, 5], clinical trials of the most widely-used anti-VEGF therapeutics, as well as comparative studies among them, have regarded visual gains as an accepted metric of therapeutic efficacy [5, 35]. Here, VEGFA is linked to blindness (disorder).